Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) Performance Status = 0 -- 2

• Cisplatin-ineligible, muscle invasive bladder cancer

• Adequate organ and marrow functions

• Women of child-bearing potential and men with partners of child-bearing potentialmust agree to use protocol specified forms of birth control

Exclusion Criteria:

• Patient simultaneously enrolled in any therapeutic clinical trial

• Current or anticipated use of other investigational agents while participating inthis study

• Psychiatric illness/social situations that would limit compliance with studyrequirements

• Pregnant or breast feeding. There is a potential for congenital abnormalities andfor this regimen to harm breast feeding infants

• Histology of pure adenocarcinoma, pure squamous cell carcinoma, or pure small cellcarcinoma in the TURBT sample

• Prior systemic chemotherapy (prior intravesical therapy is allowed) and/ or priorradiation therapy to the urinary bladder

• Uncontrolled intercurrent illness

• Current consumption of tobacco products

• History of glucose-6-phosphate dehydrogenase (G6PD) deficiency